Disease · MONDO_0001627
Comparisons in its trials15
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 15 of 15
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Irsenontrine 50 mg vs Placebo: deaths from any cause | 0 of 99 | 1 of 97 | 196 | NCT03467152 | Trial comparisons |
| Irsenontrine 50 mg vs Placebo: Number of Participants With Orthostatic Tachycardia | 0 of 99 | 1 of 97 | 196 | NCT03467152 | Trial comparisons |
| Irsenontrine 50 mg vs Placebo: serious adverse events | 7 of 99 | 9 of 97 | 196 | NCT03467152 | Trial comparisons |
| Xanamem™ vs Placebo: deaths from any cause | 0 of 91 | 0 of 94 | 185 | NCT02727699 | Trial comparisons |
| Xanamem™ vs Placebo: serious adverse events | 4 of 91 | 4 of 94 | 185 | NCT02727699 | Trial comparisons |
| Intervention Arm vs Standard of Care: deaths from any cause | 2 of 67 | 2 of 65 | 132 | NCT04117178 | Trial comparisons |
| Intervention Arm vs Standard of Care: serious adverse events | 7 of 67 | 6 of 65 | 132 | NCT04117178 | Trial comparisons |
| Active (AMX0035) vs Placebo: deaths from any cause | 0 of 51 | 0 of 44 | 95 | NCT03533257 | Trial comparisons |
| Active (AMX0035) vs Placebo: Number of Participants With Treatment-Emergent Adverse Event (TEAEs) | 34 of 51 | 26 of 44 | 95 | NCT03533257 | Trial comparisons |
| Active (AMX0035) vs Placebo: serious adverse events | 3 of 51 | 1 of 44 | 95 | NCT03533257 | Trial comparisons |
| Real Discontinuation vs Sham Discontinuation: Successful Completion | 20 of 26 | 32 of 35 | 61 | NCT02248636 | Trial comparisons |
| Real Discontinuation vs Sham Discontinuation: deaths from any cause | 0 of 26 | 1 of 35 | 61 | NCT02248636 | Trial comparisons |
| Real Discontinuation vs Sham Discontinuation: serious adverse events | 0 of 26 | 0 of 35 | 61 | NCT02248636 | Trial comparisons |
| Active Memantine vs Placebo Oral Tablet: deaths from any cause | 0 of 10 | 0 of 10 | 20 | NCT00294554 | Trial comparisons |
| Active Memantine vs Placebo Oral Tablet: serious adverse events | 0 of 10 | 0 of 10 | 20 | NCT00294554 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0001627/comparisons